Bulletin
Investor Alert

New York Markets Close in:

Cyclerion Therapeutics Inc.

NAS: CYCN

GO
/marketstate/country/us

Market open

 --Real time quotes

May 16, 2022, 11:36 a.m.

/zigman2/quotes/207301221/composite

$

0.56

Change

-0.0064 -1.13%

Volume

Volume 32,729

Real time quotes

/zigman2/quotes/207301221/composite

Previous close

$ 0.57

$ 0.56

Change

-0.0064 -1.13%

Day low

Day high

$0.54

$0.57

Open

52 week low

52 week high

$0.50

$4.86

Open

Andreas Eugen Busch

Andreas Eugen Busch is on the board of Max-Delbrück-Centrum für Molekulare Medizin (MDC), Absci Corp. and Centogene NV and Chief Scientific Officer for Cyclerion Therapeutics, Inc.

In the past he held the position of Chief Scientific Officer & Executive VP at Shire Plc, Executive VP & Head-Global Drug Discovery at Bayer HealthCare AG, Head-Global Drug Discovery at Bayer Pharma AG, Head-Cardiovascular Research at Aventis Pharma AG, Head-Cardiovascular Research at Hoechst Marion Roussel, Inc., Global Head-Cardiovascular Research at Sanofi-Aventis Groupe SA and Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main.

Andreas Eugen Busch received a doctorate from Johann Wolfgang Goethe-Universität Frankfurt am Main.

Transactions

Date Shares Transaction Value
11/09/2020 125,000   Acquisition at $2.53 per share. 316,250
11/15/2019 125,000   Acquisition at $1.82 per share. 227,500

Officers and Executives

Dr. Peter M. Hecht
Chief Executive Officer & Director
Ms. Cheryl Gault
Chief Operating Officer
Ms. Anjeza Gjino
Chief Financial Officer
Mr. Kevin Durfee
Vice President-Information Technology & Facilities
Dr. Andreas Eugen Busch
Chief Scientific Officer
Dr. G. Todd Milne
Senior Vice President-Corporate Development
Dr. Jennifer Chickering
Vice President-Clinical Strategy
Ms. Marsha H. Fanucci
Chairman
Dr. Errol B. de Souza
Independent Director
Ms. Stephanie Lovell
Independent Director
Dr. Michael E. Mendelsohn
Independent Director
Dr. Ole Isacson
Independent Director
Mr. Terrance G. McGuire
Independent Director
Mr. George H. Conrades
Independent Director
Link to MarketWatch's Slice.